Few Americans think twice about whether their medicine bottle really contains what it says on the label.
CNN's Elizabeth Cohen talks about a counterfeit version of Avastin that is being sold in the U.S.
A counterfeit version of the anti-cancer drug Avastin may have been purchased and used in a number of medical facilities in the United States, the U.S. Food and Drug Administration warned Wednesday.
A new combination of treatments can help battle some forms of metastatic breast cancer and slow down the spread of the disease, according to two separate studies.
Monday morning, Patricia Howard, 66, was at Memorial Sloan-Kettering Cancer Center in New York, undergoing scans that led doctors to declare her cancer-free -- five years after her advanced breast cancer was diagnosed.
An FDA panel debates the effectiveness of the cancer drug Avastin, which was approved under an accelerated process.
The controversial drug Avastin should be phased out as a treatment for metastatic breast cancer, the Food and Drug Administration said Thursday, citing recent studies that show its benefits may be outweighed by dangerous side effects.
The Food and Drug Administration may revoke its approval of the drug Avastin for use in breast cancer patients.
Marcia Gilbert has spent most of her life in Charlotte, North Carolina, but for the end of summer, she decided to make a special trip.
CNN's Elizabeth Cohen reports on new safety concerns about a pair of anemia drugs used to treat cancer patients.
Genentech's stock fell after the biotech raised its 2008 earnings guidance, but not enough impress investors.
A recent green light from regulators could mean a brighter outlook from Genentech when the biotech meets with analysts Friday.
Stocks advanced Monday morning as investors welcomed a report that showed a smaller-than-expected decline in existing home sales and looked to a potential bailout for troubled bond insurer Ambac Financial.
Stocks futures lost ground Monday as investors eyed weak results from home improvement retailer Lowe's and hoped for a plan to rescue bond insurer Ambac.
Drugmaker Genentech said Friday that The Food and Drug Administration has granted accelerated approval for Avastin, a drug used for the treatment of breast cancer.
Genentech, the word's largest biotech in terms of market capitalization, reported a healthy increase in sales and earnings for the fourth quarter.
CNN's Dr. Sanjay Gupta reports on a new test that could help find breast cancer tumors when they're most treatable.
Big Pharma, fueled by promising pipelines and cost-cutting, is poised for a strong 2008, analysts say, while projections are mixed for the biotech sector.
CNN's Elizabeth Cohen reports on New Jersey's new requirement that preschoolers receive flu shots.
Genentech scientists won't waste any time fretting the FDA panel decision to reject Avastin as a breast cancer treatment. The reason: The biotech giant has at least three clinical breast cancer trials underway - at least one of which is likely to succeed.
CNN's Dr. Sanjay Gupta reports on a new study linking CT scans to greater cancer risks.
Stocks rallied Wednesday, with the Dow jumping nearly 200 points, on a mix of strong economic news and bets that the Federal Reserve will cut interest rates again at its policy meeting next week.
A panel of FDA advisors did not support the use of Genentech's Avastin as a breast cancer drug.
Stocks rallied Wednesday, bouncing after a two-session slide, on strong economic news and bets that the Federal Reserve will cut interest rates again at its policy meeting next week.
Genentech Inc. faces a high-stakes decision by a government panel Wednesday over the cancer drug Avastin.
Critics say U.S. government-mandated abstinence programs aren't helping the fight against AIDS. CNN's Josh Levs reports
Genentech reported a surge in third-quarter earnings that barely beat Wall Street projections, while its revenue increase fell just short of estimates.
Genentech's growth stalled in the third quarter, according to an analyst who lowered his expectations Monday for the biotech's sales and earnings.
ImClone stock fell Friday after an analyst downgraded the biotech, based on his conversation with doctors who were hesitant to use Erbitux as a lung cancer drug.
Genentech reported a quarterly surge in earnings and revenues, handily beating Wall Street estimates.
Stalled sales, failed drug experiments and an SEC inquiry are among the problems nagging at Amgen and Genentech as the world's two biggest biotech companies get set to report first-quarter earnings.
Senior Democrats and Republicans in Congress are hard at work on bills that would provide millions of Americans with cheaper copies of biotech drugs that can cost hundreds of thousands of dollars a year, a news report said Saturday.
The FDA is warning people - especially pregnant women and girls - not to buy the acne treatment Accutane online because of its potentially dangerous side effects.
The biotech ImClone's stock price surged Friday following some bad news about its competitor Amgen's cancer drug Vectibix.
Genentech will unveil new details this weekend on tests of Avastin, one of its biggest-selling medicines, as it seeks to find new markets for the cancer drug.
The biotech Genentech reported a surge in earnings for 2006 and beat analyst projections for the fourth quarter.
New study results could broaden the use of colon cancer drug Erbitux, but analysts have mixed opinions as to whether this means a boost in sales and royalties for ImClone and Bristol-Myers Squibb.
Biotechs didn't do so well in 2006, but analysts are expecting a strong recovery for 2007, particularly for Big Biotech.
Susan Desmond-Hellmann, President, Product Development of Genentech, ranks No. 17 on Fortune's 2006 list of 50 Most Powerful Women.
Genentech reported third-quarter net earnings Tuesday that topped expectations, but shares for the biotech developer fell in after-hours trading because of concern about some drug sales.
Stocks slumped Wednesday, with tech-sector woes spreading to the broader market, amid concerns about corporate profit growth, geopolitical tensions and the mix of higher inflation and slower economic growth.
Tech stocks continued to erode Wednesday morning, while the broader market wobbled, as investors were cautious ahead of an onslaught of second-quarter earnings reports.
With investors awaiting reports on the nation's trade balance and petroleum inventory, U.S. stocks were set to open mixed Wednesday.
Stocks snapped back Tuesday, recovering after a tough session marred by worries about corporate earnings. Upbeat news in the chip sector and strength in oil and gold stocks were among the factors leading the comeback.
Amgen and Genentech, the long-ruling kings of the cancer drug market, could find the lucrative business growing more crowded as potential new competitors come to market.
For Fred Holper of Keyport, N.J., facing a diagnosis of terminal colon cancer at the age of 48 was tough, but his treatment decision wasn't. Immediately after surgery in 2001, he joined a clinical ...
Genentech, the second-biggest biotech in the world, just got cheaper.
Genentech's stock jumped more than 5 percent on Friday after the biotech said its earnings would surge by up to 50 percent in 2006.
Domagoj Vucic didn't come to Genentech for the rich stock options or the free cappuccino or the made-to-order sushi or the parties every Friday night. He came from the University of Georgia seven years ago because he believed Genentech could help him answer a burning question: What is it that keeps caterpillars infected with baculovirus alive for an entire seven days before they explode into a gooey puddle? Figuring that one out could, believe it or not, be a big step toward curing cancer. Doctor-scientist Napoleone Ferrara didn't come for the perks either. He joined Genentech in 1988 because the company would allow him to pursue an obsession: the study of the formation of blood vessels that feed, say, a tumor, and the search for an antibody to disrupt the process.
U.S. stock indexes were poised for a mixed opening at Wednesday's open, after a disappointing outlook from Dow component DuPont as well as a downgrade of Yahoo! took some of the steam out of the market.
Genentech is still the darling of the biotech industry. The problem is everyone knows it.
Investors who stuck with their biotech stocks this year are sitting pretty but will the good times roll through 2006?
I WAS GENENTECH'S chief medical officer when we began clinical-trial studies of Avastin in 1997. The hypothesis was that Avastin could stun a tumor--keep it from growing beyond the size of a BB pel...
Drug sales for cancer treatments are expected to more than double over the next five years, with cancer drugs replacing cholesterol-reducers as the number one pharmaceutical sector, according to a report from IMS Health.
GlaxoSmithKline has thrown its big pharma weight behind an experimental anti-cancer drug being tested by Human Genome Sciences.
European stocks ended steady Tuesday as drugmakers AstraZeneca and Roche rose on improving prospects for their cancer drugs, but weakness in U.S. shares weighed on the broader market.
Pfizer is planning to launch a new drug, possibly by year-end, to treat a rare but deadly form of stomach cancer, that could bring in up to $800 million a year for the world's biggest drugmaker, an industry analyst said Monday.
Herceptin, Genentech's drug for fighting some late-stage breast cancer, could potentially double its sales if approved by the Food and Drug Administration to fight cancer in the early stages.
Genentech could be one of the most promising biotechs on the market, but is its share price justified?
For the head of any public company, growth, like yardwork, is the job that's never done--the new blanket of autumn leaves falling before you're able to haul the first batch away. "Growth is the big...
First-quarter earnings reports start pouring in this week, and by all accounts, they're primed to please. What's in question is whether the strong earnings will ail the rangebound stock market.
It's strange to think that I can still remember the smell after all this time. The year was 1978, not long after my 15th birthday, and I'd sneaked into my brother's bedroom. There, on a wall of she...
After more than 30 years, how fares the war on cancer? Much worse than you'd think, especially if you've been wowed by news of the recent approval of wonder drugs such as Avastin or Erbitux. Despit...
News that gross domestic product grew at a faster-than-expected pace in the fourth quarter soothed investors but had little impact on U.S. stocks early Friday, with market participants still edgy that stocks have run too far too fast.
The basic idea behind antiangiogenesis is simple: To stop a tumor, you must starve it to death. Yet, like many simple ideas, this one has been difficult to achieve--until now. Antiangiogenic drugs...
In late June, Arthur Levinson was talking with MONEY's Erica Garcia in his corner office in south San Francisco, nervously shaking a sneaker-clad foot while awaiting the decision from the Food and ...
In late June, Arthur Levinson was talking with MONEY's Erica Garcia in his corner office in south San Francisco, nervously shaking a sneaker-clad foot while awaiting the decision from the Food and Drug Administration on Xolair, Genentech's asthma treatment.
In April we called Genentech "the brightest star in the [biotech] sector." Our confidence was vindicated in May, when shares of Genentech (DNA), the second-largest biotech, shot up a whopping 45% i...
Michael King's self-proclaimed "day from hell" started just after midnight on May 19. That was when Banc of America Securities released a report by the biotech analyst urging clients to sell shares...
When Genentech announced the clinical success of its new cancer drug, Avastin, on May 19, investors were having a terrible Monday. Most stocks got clobbered--at the close the Dow had sweated off 18...